Immunomodulatory tool

A61K31/305 -

 

(57) Abstract:

The invention relates to medicine and can be used to treat patients with cancer, immunodeficiency different origin, viral, microbial, parasitic, radiation diseases, and as a means for conflict prevention incompatible transplant, analgesic and prevention of various diseases. For patients using immunomodulatory agent of the following composition, wt.%: the sublimate 0,033, dry, sweet natural grape wine or whey from 3.3% sugar content up to 100. The drug is non-toxic. Its use does not adversely affect the red blood cells. The drug selectively acts on the abnormal cells of malignant tumors, while easily tolerated by patients of all age groups.

The invention relates to medicine and can be used for the treatment of patients with malignant diseases irrespective of their origin and localization, immunodeficiency different origin, viral, microbial, parasitic, radiation diseases, may be used to prevent the conflict is haunted medicines showing immunomodulatory properties, and immunomodulators are represented by compounds of different chemical structure, which can be obtained as by chemical means, and the selection of appropriate components, exhibiting a specified activity, from raw materials of vegetable and animal origin.

You know the "Adjuvant" exhibiting immunomodulatory action. The drug is a complex polypeptide fractions isolated from the thymus gland of cattle.

Apply 1-2 ml of isotonic/m as immunostimulant and biostimulant diseases, accompanied by a decrease in cellular immunity, including acute and chronic suppurative processes and inflammatory diseases, burn disease, when the depression of the immune and hematopoietic function after radiation or chemotherapy in cancer patients [1]

The objective of the invention is to optimize the activity flow of the immune processes, due to the reversible reactions of ions of mercury with sulfhydryl groups of enzymes, including coenzyme A, receptors, growth factors, steroid hormone receptors, adrenergic receptors, proteksi loopholes, antiviral, anti-radiation, antimicrobial, antiparasitic defenses, and redundant system defenses ions of mercury, the phenomenon of rupture of the disulfide bonds of all growth factors, antibodies, some hormones, receptors of erythrocytes and lymphocytes. Specific property disulfide bond to either hydrolyzed in the presence of mercury ions, this property can be used to prevent conflicts between incompatible transplant.

The problem is solved by using composition-based dichloride mercury semi-dry, semi-sweet, natural grape wine or milk serum from 3.3% sugar content.

The active drug is mercuric chloride, which is used in the solution than liquidated toxic effects tools.

Solutions of mercuric chloride in tens times less reactive compared to the crystals, since the dielectric constant of water is 80, the energy of electrostatic repulsion of particles in it 80 times smaller molecule and 80 times more stable and less reaktsionnosposobnykh.

Taken inside in the proposed concentration solution of mercuric chloride for 6 h at 93% return the weave of 3.3% help maintain an acidic environment by fermentation, improve the taste of the medicine.

Reversible blocking of sulfhydryl groups of receptors, growth factors, steroid hormone receptors and adrenergic receptors ions of mercury stops tumor growth.

Duplicate antitumor protection break disulfide bonds of growth factors, immunoglobulins and receptors of lymphocytes in the presence of mercury ions.

The proposed immunostimulant has the following composition: Sublimate 0,033 g

Semi-dry, semi-sweet,

natural grape

wine or

Whey

from 3.3% sugar content Up to 100 ml

Prepare medication as follows.

0,033 g of mercuric chloride dissolved in 100 ml of dry, sweet, natural grape wine or the whey from 3.3% sugar content.

Given that mercury compounds easily form an amalgam with the metal, in order to avoid the reduction of the activity of the drug should avoid contact of the drug with metals. The resulting solution was kept for weeks in a cool place at a temperature not exceeding 15aboutIn the dark place. After manufacturing the drug store in a bowl of yedinenii tartaric acid, therefore, before use, the solution should be shaken. Biological properties of the drug persist for a long time.

The method of treatment consists in the following. Drug taking 5 ml of the first 3 days, followed by 10 ml for 30 min before a meal, inside, and also applied externally in the form of applications. Taking the drug through a glass or plastic tube. Treatment 1 month, after a month's break, if necessary, repeat the treatment, however, observe a strict diet.

For the period from 15.09.92 on 20.03.93, we observed 336 people with cancer at different stages of the neoplastic process. Of these 316 people were treated in the outpatient form, and 20 people in the hospital. The 147 people from treated on an outpatient basis, and in 13 patients treated in hospital, the diagnosis is confirmed by histological studies.

The task was to monitor the clinical manifestations of the application of the proposed medicines, as well as the study of changes in the immunological parameters during treatment with the drug.

When solving a task in the context of studying and attornye methods.

In the process of inpatient treatment was carried out dynamic monitoring of the General condition and health of patients. At the end of the 30-day inpatient course was conducted by a medical examination. When the second course diagnostic tests in Oncology center were also conducted before and after treatment.

The analysis of the results of clinical research allows to draw the following conclusions:

Patients with benign tumors have a tendency to the complete disappearance of tumors, therefore, the method of treatment offered by the drug may be a method of cancer prevention.

In patients with malignant neoplasms after two courses complete disappearance of malignant neoplasms has not occurred (treatment method involves at least hold 3 courses of treatment with two months break in stage I-II), but already at this stage identified:

improving the General condition of most patients;

decrease in pain;

a number of patients observed decrease in the tumor size, regional lymph nodes and distant metastases;

some patients reported disappearance of major complications S="ptx2">

Material for the study of immunomodulating actions served samples of venous blood, which was taken from the cubital vein in the morning.

To evaluate the results of treatment were used generally accepted in modern clinical immunology laboratory methods.

Determination of total T-lymphocytes and their subpopulations with a calculation of the ratio as t helper cells: Tsupressory.

Determination of the total number of lymphocytes.

The determination of the number of b cells among total lymphocytes.

Quantitative determination of immunoglobulins major isotypes G, M, A, radial immunodiffusion methods.

Quantitative determination of circulating immune complexes by precipitation with PEG-6000 and based on the spectrophotometer at a wavelength of 450 nm.

Cytochemical characterization of enzyme activity faguoqitirute blood cells nst-test (spontaneous and induced prodigiozana.

The activity of the phagocytic reaction with latex particles and the calculation of phagocytic number (the number of cells with the phenomena of capture of particles at different stages of phagocytosis (and phagocytic immune system has the following changes:

The total number of lymphocytes decreased in most patients, some increased;

the number of T-lymphocytes decreased in most patients, some patients increased;

the number of T-suppressor lymphocytes (cytotoxic T-cells decreased in almost all surveyed;

the number of T-lymphocytes helpers /inductors part of patients decreased, the other part has increased;

the ratio of Tx:Twithincreased in almost all patients.

The level of b-lymphocytes In half of the patients increased, the other decreased and was below the norm.

Dynamics of changes in the levels of immunoglobulins major isotypes and circulating immune complexes after the first course of treatment:

changes in the content of immunoglobulins and immune complexes in the serum wore irregular. Thus, changes in the concentration of immunoglobulins wore izotopicheskii nature, i.e. depending on the isotype of the immunoglobulin curve of his changes was different. The concentration of immunoglobulin isotypes G and decreased, and the levels of immunoglobulin M increased in different degrees of increase.

The dynamics of change the initial data show, the phagocytic activity of the reaction and the willingness of phagocytes to the functional activity of all patients do not have significant deviations from the norm.

After the first course of treatment may be noted the increase of spontaneous cytochemical activity of neutrophils in all patients on the background of a slight decline induced prodigiozana cytochemical reactions. This activity of phagocytes against cytochemical picture is confirmed by the fact that the number phagocytosing of latex particles (phagocytic index) also increases in all cases on the background of a slight decrease in neutrophilic granulocytes, seized phagocytophilia particles. Differences in the number of source-level cells compared with those with the re-examination within the error of the experience.

A survey of patients who received 2-3 course of therapy, after 6 months from the start of treatment.

Dynamics of changes of T-lymphocytes and their subpopulations:

after 6 months since start of treatment when comparing the figures it can be stated that the total number of lymphocytes in all patients increased 1.5-2 times and is 1200-1400 cells/ml in Only one patient, it does not reach the standards, although increased 2 times from 440 d is B>:Twith. In patients it decreased. The dysregulation of subpopulations as a sign of a compromised immune reactivity of the organism at this stage of the examination takes place, however, it does not affect humoral immunity, and is limited to the relationship of cell populations.

The dynamics of changes in the content of b-lymphocytes:

Comparison of data with those in the previous stage of the survey shows that the number of b-lymphocytes increased slightly in some patients and at the same time in other patients it decreased.

Dynamics of immunoglobulins and the CEC: the most distinctive and positive feature of a change in the level of immunoglobulins was, that after 2-3 courses of treatment increases the concentration of IgG in the 1.5-3.5 times, and the concentration of IgA 1.2-2.1 times; IgM level in all patients declined from 0.55 to 0.76 g/l, slightly lower than the average physiological norm. Circulating immune complexes in all patients decreased to normal values, which can also be regarded as a positive sign of immunological reactivity.

Phagocytic reaction: spontaneous cytochemical activity slightly (within error experience) decreased some what of all cases increased 1.5-1.8 times against the background of larger or smaller increase in phagocytic activity of neutrophils. In 2 cases the phagocytic activity as the number of cells that engulfed the latex particles decreased from 84% to 51%

Immunological evaluation of patients treated with the proposed drug, allows to make a conclusion about the immunomodulating effect of the drug.

IMMUNOMODULATORY AGENT containing the active principle and a solvent, characterized in that the active principle tool contains mercuric chloride and the active medium is in the form of dry, sweet natural grape wine or whey from 3.3% sugar content in the following ratio, wt.

The sublimate 0,033

Dry, sweet natural grape wine or

whey from 3.3% sugar content Else

 

Same patents:
Up!